[Asia Economy Reporter Lee Gwanju] Aliko Pharmaceutical announced on the 9th that its sales in the first quarter of this year amounted to 42.9 billion KRW, a 37% increase compared to the same period last year. Operating profit reached 3.3 billion KRW, nearly doubling by 99% from last year.
The company explained that due to the impact of COVID-19, sales of ETC (ethical drugs) products focused on allergy and respiratory diseases such as Eldosin, Umkae, and Alikof grew, and existing ETC products like Colliatin (cerebrovascular disease treatment), Cres (dyslipidemia treatment), and Nexirium (gastrointestinal treatment) also showed strong performance, setting a record high quarterly sales.
Sales from the specialized business, which Aliko Pharmaceutical is promoting as a new business, recorded 1.1 billion KRW. Sales in the first quarter of last year, when the specialized business started, were about 100 million KRW, showing growth in performance within one year.
In particular, the company stated that the adhesive wound dressing for scar management, ‘Lenoska,’ is smoothly entering major tertiary general hospitals and accelerating the expansion of the medical device market. Lenoska, launched in 2020, is a wound dressing developed in-house by Aliko Pharmaceutical and has recently passed the new material review at major tertiary general hospitals such as Seoul National University Hospital and Sinchon Severance Hospital, where it is currently in use. It is also registered and prescribed as a scar management material at major burn centers nationwide.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
